^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + LY3009120 (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations
Excerpt:
Antitumor activity of cetuximab and LSN3074753 combination in single-mouse colorectal cancer PDX trial....In CTG0358 model with atypical BRAF G596V and NRAS mutations, both cetuximab and LSN3074753 showed minimal antitumor activity, and the combination of these two agents caused tumor stasis while the animal was on treatment (Fig. 4E).
DOI:
10.1158/1078-0432.CCR-16-3250
